Stay updated on Adjunctive Effects of Psilocybin & Buprenorphine Formulation Clinical Trial

Sign up to get notified when there's something new on the Adjunctive Effects of Psilocybin & Buprenorphine Formulation Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjunctive Effects of Psilocybin & Buprenorphine Formulation Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in a clinical trial study aiming to evaluate the safety and adjunctive effects of psilocybin in adults with opioid use disorder maintained on a buprenorphine/naloxone formulation.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:59.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' The new description provides examples of eligibility criteria, such as a person's general health condition or prior treatments, and includes detailed inclusion and exclusion criteria for the study.
    Difference
    25%
    Check dated 2024-05-22T21:14:49.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:26:15.000Z thumbnail image

Stay in the know with updates to Adjunctive Effects of Psilocybin & Buprenorphine Formulation Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjunctive Effects of Psilocybin & Buprenorphine Formulation Clinical Trial page.